Skip to Content

Cresemba

Generic Name: Isavuconazonium Sulfate
Class: Azoles
Chemical Name: [2-[[[1-[1-[(2R,3R)-3-[4-( 4-Cyanophenyl)-2-thiazolyl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4H-1,2,4-triazolium-4-yl]ethoxy]carbonyl]methylamino]-3-pyridinyl]methyl ester-N-methyl-glycine sulfate (1:1)
Molecular Formula: C35H35F2N8O5S•HO4SC22H17F2N5OS
CAS Number: 946075-13-4

Medically reviewed by Drugs.com. Last updated on Sep 9, 2019.

Introduction

Antifungal; azole (triazole derivative); prodrug of isavuconazole.1 5 6 7 8

Uses for Cresemba

Aspergillosis

Treatment of invasive aspergillosis;1 8 29 designated an orphan drug by FDA for this indication.2

IDSA considers IV voriconazole the drug of choice for primary treatment of invasive aspergillosis;423 amphotericin B and isavuconazonium recommended as alternatives for primary treatment.423 For salvage therapy in patients refractory to or intolerant of primary antifungal therapy, IDSA recommends IV amphotericin B, an IV echinocandin (caspofungin, micafungin), oral or IV posaconazole, or itraconazole oral suspension.423

Consult current IDSA clinical practice guidelines available at [Web] for additional information on management of aspergillosis.423

Mucormycosis

Treatment of invasive mucormycosis;1 8 30 designated an orphan drug by FDA for this indication.2

Esophageal Candidiasis

Treatment of esophageal candidiasis.16 440

Esophageal candidiasis requires treatment with a systemic antifungal (not a topical antifungal).425 440

IDSA recommends oral fluconazole as the preferred drug of choice for treatment of esophageal candidiasis;425 if oral therapy not tolerated, IV fluconazole or an IV echinocandin (anidulafungin, caspofungin, micafungin) recommended.425

For treatment of esophageal candidiasis in HIV-infected adults, CDC, NIH, and IDSA recommend oral or IV fluconazole or itraconazole oral solution.440 Oral or IV voriconazole, oral isavuconazonium, an IV echinocandin (anidulafungin, caspofungin, micafungin), or IV amphotericin B recommended as alternatives.440

Consult current IDSA clinical practice guidelines available at [Web]425 and current CDC, NIH, and IDSA clinical practice guidelines for prevention and treatment of opportunistic infections in HIV-infected individuals available at [Web]440 for additional information on management of esophageal candidiasis.

Candidemia and Other Invasive Candida Infections

Has been used for treatment of candidemia and other invasive infections caused by Candida;17 designated an orphan drug by FDA for treatment of invasive candidiasis/candidemia.2

Cresemba Dosage and Administration

Administration

Administer orally or by IV infusion.1

Oral Administration

Administer capsules orally without regard to meals.1

Swallow whole; do not chew, crush, dissolve, or open.1

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer only by IV infusion;1 do not administer by rapid or direct IV injection.1

Must be reconstituted and further diluted prior to IV infusion.1

Do not infuse simultaneously with other IV drugs.1

If same IV line used for sequential infusion of several different drugs, flush IV line with 0.9% sodium chloride or 5% dextrose injection before and after infusion.1

Must be infused using infusion set with inline membrane filter with pore size of 0.2–1.2 µm.1

Vials contain no preservatives;1 for single use only.1

Reconstitution and Dilution

Reconstitute vial containing 372 mg of isavuconazonium sulfate by adding 5 mL of sterile water for injection.1 Gently shake to dissolve the lyophilized powder.1

Inspect for particulate matter and discoloration;1 reconstituted solution should appear clear and free of visible particulates.1

Immediately dilute reconstituted solution or, alternatively, store at <25°C for maximum of 1 hour prior to dilution.1

To dilute, remove 5 mL of reconstituted solution from vial and add to IV bag containing 250 mL of 0.9% sodium chloride injection or 5% dextrose injection to provide a solution containing approximately 1.5 mg of isavuconazonium sulfate per mL.1

Translucent to white particulates of isavuconazole may be visible in the diluted solution;1 gently mix or roll IV bag to minimize formation of particulates.1 Avoid unnecessary vibration or vigorous shaking;1 do not transport the solution using a pneumatic transport system.1

Because the reconstituted and diluted solution must be administered using infusion set with inline membrane filter with a pore size of 0.2–1.2 µm, apply reminder sticker to the IV bag.1

Complete IV infusion within 6 hours after dilution when stored at room temperature.1 If refrigerated at 2–8°C immediately after dilution, complete IV infusion within 24 hours after dilution.1

Rate of Administration

Administer by IV infusion over ≥1 hour.1

Dosage

Available as isavuconazonium sulfate (inactive prodrug of isavuconazole).1

Dosage usually expressed in terms of isavuconazonium sulfate;1 also has been expressed in terms of isavuconazole.8 16 17 423 440

Each 186 mg of isavuconazonium sulfate is equivalent to 100 mg of isavuconazole.1

Oral and IV dosages are identical.1 Switching between oral and IV routes is acceptable;1 loading dosage not needed when switching between oral and IV preparations.1

Adults

Aspergillosis
Oral or IV

Loading dosage of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) every 8 hours for 6 doses;1 423 12–24 hours after final loading dose, begin maintenance dosage of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) once every 24 hours.1 423

Base total duration of treatment on severity of underlying disease, recovery from immunosuppression, and response to the drug.1 423 In a clinical study, mean duration of treatment was 45 days and protocol-defined maximum treatment duration was 84 days.29 IDSA recommends treatment of invasive pulmonary aspergillosis be continued for at least 6–12 weeks.423

Mucormycosis
Oral or IV

Loading dosage of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) every 8 hours for 6 doses;1 12–24 hours after final loading dose, begin maintenance dosage of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) once every 24 hours.1

Base total duration of treatment on severity of underlying disease, recovery from immunosuppression, and response to the drug.1 In a clinical study, median duration of treatment was 102, 33, or 85 days in those receiving the drug for initial treatment (primary treatment), disease refractory to other antifungal therapy, or intolerance to other antifungal therapy, respectively.1 3

Esophageal Candidiasis
Oral

HIV-infected adults: Loading dose of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) followed by 93 mg of isavuconazonium sulfate (equivalent to 50 mg of isavuconazole) once daily or loading dose of 744 mg of isavuconazonium sulfate (equivalent to 400 mg of isavuconazole) followed by 186 mg of isavuconazonium sulfate (equivalent to 100 mg of isavuconazole) once daily.440 Alternatively, 744 mg of isavuconazonium sulfate (equivalent to 400 mg of isavuconazole) once weekly.440

CDC, NIH, and IDSA recommend treatment of esophageal candidiasis be continued for 14–21 days.440

Special Populations

Hepatic Impairment

Mild or moderate hepatic impairment (Child-Pugh class A or B): Manufacturer states dosage adjustments not necessary.1 Some clinicians suggest that reduced dosage be considered.12

Severe hepatic impairment (Child-Pugh class C): Dosage recommendations not available;1 pharmacokinetics not studied.1 Use in such patients only when benefits outweigh risks.1 (See Hepatic Impairment under Cautions.)

Renal Impairment

Dosage adjustments not needed in adults with mild, moderate, or severe renal impairment, including those with end-stage renal disease.1 (See Renal Impairment under Cautions.)

Geriatric Patients

Dosage adjustments not needed based on age and gender.1

Cautions for Cresemba

Contraindications

  • Hypersensitivity to isavuconazole (active metabolite of isavuconazonium).1

  • Familial short QT syndrome.1 (See Cardiovascular Effects under Cautions.)

  • Concomitant use with potent CYP3A4 inhibitors or inducers.1 (See Interactions.)

Warnings/Precautions

Sensitivity Reactions

Serious hypersensitivity (e.g., anaphylaxis) and severe skin reactions (e.g., Stevens-Johnson syndrome) reported in patients receiving other azole antifungals.1

Data regarding cross-sensitivity with other azole antifungals not available.1 Use with caution in patients hypersensitive to other azoles.1

If severe adverse cutaneous reaction occurs, discontinue isavuconazonium.1

Hepatic Effects

Serious hepatic effects, including hepatitis, cholestasis, and hepatic failure (sometimes fatal), reported in patients with serious underlying medical conditions (e.g., hematologic malignancy) receiving an azole antifungal, including isavuconazonium.1

Less severe hepatic effects (e.g., increased ALT, AST, alkaline phosphatase, total bilirubin concentrations) also reported.1 Liver function test elevations generally were reversible and did not require discontinuance of isavuconazonium.1

Perform liver function tests prior to and monitor during isavuconazonium therapy.1 If abnormal liver function tests occur during therapy, monitor for development of more severe hepatic injury.1 If signs and symptoms of liver disease occur, discontinue isavuconazonium.1

Infusion Reactions

Infusion reactions (e.g., hypotension, dyspnea, chills, dizziness, paresthesia, hypoesthesia) reported.1

To reduce risk of infusion reactions, dilute reconstituted solution in 250 mL of compatible diluent and administer by IV infusion over ≥1 hour.1 (See IV Administration under Dosage and Administration.)

If infusion reaction occurs, discontinue the IV infusion.1

Fetal/Neonatal Morbidity and Mortality

May cause fetal harm.1 Has been associated with increased perinatal mortality and skeletal abnormalities in animals;1 skeletal abnormalities also observed in animal studies evaluating other azole antifungals.1

Use during pregnancy only if potential benefits to the woman outweigh potential risks to fetus.1 (See Pregnancy under Cautions.)

Cardiovascular Effects

Shortens corrected QT (QTc) interval in a dose-related manner.1 Contraindicated in patients with familial short QT syndrome (see Contraindications under Cautions).1 Concomitant use with other drugs that shorten QTc interval not evaluated.1 (See Drugs that Shorten the QT Interval under Interactions.)

Atrial fibrillation, atrial flutter, bradycardia, palpitations, supraventricular extrasystoles, supraventricular tachycardia, ventricular extrasystoles, and cardiac arrest also reported.1

Interactions

Concomitant use with drugs that are potent CYP3A4 inhibitors (e.g., ketoconazole, high-dose ritonavir) or inducers (e.g., rifampin, carbamazepine, St. John's wort [Hypericum perforatum], long-acting barbiturates) is contraindicated.1 (See Interactions.)

Administration Precautions

IV solutions of isavuconazonium must be given by IV infusion through an inline filter to remove any insoluble particulates that may be present.1 (See IV Administration under Dosage and Administration.)

Selection and Use of Antifungals

Prior to initiation of isavuconazonium, obtain appropriate specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s).1 May be started pending availability of results, but adjust antifungal therapy as needed when results become available.1

Information on test methods and quality control standards for in vitro susceptibility testing of antifungal agents and specific interpretive criteria for such testing recognized by FDA is available at [Web].1

Specific Populations

Pregnancy

Category C.1

Use during pregnancy only if potential benefits to the woman justify potential risks to fetus.1

No adequate and well-controlled studies in pregnant women.1 Based on data from animal reproduction studies, isavuconazonium is predicted to have the potential for increasing the risk of adverse developmental outcomes above background risk.1

Lactation

Distributed into milk in rats.1 Do not breast-feed while receiving isavuconazonium.1

Pediatric Use

Safety and efficacy not established in patients <18 years of age.1

Geriatric Use

No substantial difference in pharmacokinetics between geriatric and younger adults.1

Hepatic Impairment

Mild or moderate hepatic impairment (Child-Pugh class A or B): AUC increased, systemic clearance decreased, half-life prolonged.1 12 Clinical importance unknown.12

Severe hepatic impairment (Child-Pugh class C): Use isavuconazonium only if benefits outweigh risks.1 If used in such patients, monitor for adverse effects.1 Pharmacokinetics not evaluated.1

Renal Impairment

Mild, moderate, or severe renal impairment: No clinically important effects on pharmacokinetics.1

Common Adverse Effects

GI effects (nausea, vomiting, diarrhea, abdominal pain, constipation, dyspepsia, decreased appetite),1 elevated bilirubin and liver enzymes (e.g., ALT, AST, alkaline phosphatase, γ-glutamyltransferase),1 metabolic effects (hypokalemia, hypomagnesemia),1 respiratory effects (dyspnea, cough, acute respiratory failure),1 headache,1 fatigue,1 insomnia,1 back pain,1 chest pain,1 peripheral edema,1 hypotension,1 renal failure,1 delirium (e.g., agitation, confusional state, disorientation, mental status changes),1 anxiety,1 rash,1 pruritus,1 administration site reactions.1

Interactions for Cresemba

Because isavuconazonium rapidly metabolized to isavuconazole in vivo, interactions are reported for isavuconazole.1

Isavuconazole is metabolized by CYP3A4 and 3A5 and subsequently by UGT.1

Moderate inhibitor of CYP3A4;1 inhibits CYP2C8, 2C9, 2C19, and 2D6 in vitro.1 Induces CYP3A4, 2B6, 2C8, and 2C9 in vitro.1

Weak inhibitor of P-glycoprotein (P-gp) and organic cation transporter (OCT) 2.1 Also inhibits breast cancer resistance protein (BCRP).1 Does not inhibit organic anion transporting polypeptide (OATP) 1B1 or OATP1B3.15

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Concomitant use with potent CYP3A4 inhibitors or inducers may increase or decrease plasma concentrations of isavuconazole, respectively, and is contraindicated.1

Drugs Affecting or Affected by Membrane Transporters

If used concomitantly with drugs that are P-gp substrates and have a narrow therapeutic index, dosage adjustment of the P-gp substrate may be required.1

Drugs that Shorten the QT Interval

Possibility of additive effects if used concomitantly with drugs that shorten the QT interval not evaluated to date.1 (See Cardiovascular Effects under Cautions.)

Specific Drugs

Drug

Interaction

Comments

Antiretrovirals, HIV entry and fusion inhibitors

Maraviroc: Potential increased maraviroc concentrations200

Maraviroc: Use maraviroc dosage of 150 mg twice daily200

Antiretrovirals, HIV integrase inhibitors (INSTIs)

Bictegravir: Potential increased bictegravir concentrations200

Cobicistat-boosted elvitegravir: Increased isavuconazole concentrations expected; increased elvitegravir and cobicistat concentrations possible200

Bictegravir: Dosage adjustments not needed200

Cobicistat-boosted elvitegravir: Consider monitoring isavuconazole concentrations and assessing virologic response200

Antiretrovirals, HIV nonnucleoside reverse transcriptase inhibitors (NNRTIs)

Doravirine or rilpivirine: Possible increased concentrations of the NNRTI200

Efavirenz, etravirine, or nevirapine: Potential decreased isavuconazole concentrations200

Doravirine or rilpivirine: Dosage adjustments not needed200

Efavirenz, etravirine, or nevirapine: May need to adjust dosage of the antifungal;200 consider monitoring isavuconazole concentrations and antifungal response200

Antiretrovirals, HIV protease inhibitors (PIs)

Fixed combination of lopinavir and ritonavir (lopinavir/ritonavir): Increased isavuconazole peak concentrations and AUCs;1 200 decreased lopinavir and ritonavir AUCs and potential loss of antiretroviral efficacy1 200

High-dose ritonavir (400 mg twice daily): Potential increased isavuconazole exposure1

Other HIV PIs: Potential increased isavuconazole concentrations and altered HIV PI concentrations200

Lopinavir/ritonavir: Use concomitantly with caution;1 consider monitoring isavuconazole concentrations and toxicities and assessing virologic response200

High-dose ritonavir (400 mg twice daily): Concomitant use contraindicated1

Other HIV PIs: Consider monitoring isavuconazole concentrations and toxicity;200 also consider monitoring HIV PI toxicities and virologic response200

Atorvastatin

Potential increased atorvastatin exposure1

Use concomitantly with caution;1 monitor for atorvastatin-related adverse effects1

Barbiturates, long-acting

Potential decreased isavuconazole exposure1

Concomitant use contraindicated1

Bupropion

Decreased bupropion exposure1

Use concomitantly with caution;1 increased bupropion dosage may be needed (do not exceed maximum recommended dosage)1

Caffeine

No clinically important effects on caffeine pharmacokinetics1 15

Carbamazepine

Potential decreased isavuconazole exposure1

Concomitant use contraindicated1

Cyclophosphamide

Use concomitantly with caution4

Dextromethorphan

No clinically important effects on dextromethorphan pharmacokinetics1 15

Digoxin

Increased digoxin exposure1

Use concomitantly with caution;1 monitor digoxin concentrations and adjust digoxin dosage accordingly1

Efavirenz

Use concomitantly with caution4

Estrogens/Progestins

Oral contraceptives containing ethinyl estradiol and norethindrone: No clinically important effects on ethinyl estradiol or norethindrone pharmacokinetics1 15

Immunosuppressive agents (cyclosporine, mycophenolate mofetil, sirolimus, tacrolimus)

Cyclosporine, sirolimus, tacrolimus: Increased concentrations and AUC of the immunosuppressive agent1

Mycophenolate mofetil: Increased mycophenolic acid exposure1

Cyclosporine, sirolimus, tacrolimus: Use concomitantly with caution;1 monitor concentrations of the immunosuppressive agent and adjust immunosuppressive agent dosage accordingly1

Mycophenolate mofetil: Use concomitantly with caution;1 monitor for mycophenolic acid-related toxicities1

Ketoconazole

Increased peak concentrations and AUC of isavuconazole1

Concomitant use contraindicated1

Metformin

No clinically important effects on metformin pharmacokinetics1 15

Methadone

No clinically important effects on methadone pharmacokinetics1 15

Methotrexate

No clinically important effects on methotrexate pharmacokinetics1 15

Midazolam

Increased midazolam exposure1

Use concomitantly with caution;1 consider reducing midazolam dosage1

Prednisone

No clinically important effects on prednisone pharmacokinetics1 15

Proton-pump inhibitors (esomeprazole, omeprazole)

Esomeprazole: No clinically important effects on isavuconazole pharmacokinetics1

Omeprazole: No clinically important effects on omeprazole pharmacokinetics1 15

Repaglinide

No clinically important effects on repaglinide pharmacokinetics1 15

Rifampin

Decreased peak concentrations and AUC of isavuconazole1

Concomitant use contraindicated1

St. John's wort (Hypericum perforatum)

Potential decreased isavuconazole exposure1

Concomitant use contraindicated1

Warfarin

No clinically important effects on warfarin pharmacokinetics1 15

Cresemba Pharmacokinetics

Absorption

Bioavailability

Following oral or IV administration, isavuconazonium sulfate is rapidly and almost completely (>98%) hydrolyzed by esterases in the blood to yield the active moiety, isavuconazole, and an inactive cleavage product.1 10 11

Well absorbed following oral administration (absolute bioavailability 98%).1

Peak plasma concentrations achieved in approximately 2–4 hours after oral administration1 10 11 or 0.7–1 hour after start of IV infusion.1 10

Food

Administration with high-fat meal has no clinically important effect on oral absorption.1

Plasma Concentrations

Steady-state concentrations probably not achieved until after 2 weeks.11

Special Populations

Reduced bioavailability possible in patients with Roux-en-Y gastric bypass.13

Distribution

Extent

Extensively distributed into tissues.1 10

Distributed into milk in rats.1

Plasma Protein Binding

>99% (mainly albumin).1 10

Elimination

Metabolism

In vivo studies indicate isavuconazole is metabolized by CYP3A4 and 3A5 and, subsequently, by UGT.1

Elimination Route

Following oral administration of radiolabeled isavuconazonium sulfate, 46% of total radioactive dose recovered in feces (approximately 33% as isavuconazole) and 46% recovered in urine (principally as metabolites of isavuconazole and metabolites of the inactive cleavage product).1 4

Only negligible amounts (<1%) of a dose of isavuconazonium sulfate are eliminated in urine as active isavuconazole.1 10

Isavuconazole is not readily dialyzable.1

Half-life

Single-dose study in adults using oral or IV isavuconazonium sulfate indicates mean distribution half-life of isavuconazole is 1.7–2.1 or 0.42–1.6 hours, respectively, and mean terminal elimination half-life of isavuconazole is 56–77 or 76–104 hours, respectively.10

Special Populations

Mild or moderate hepatic impairment (Child-Pugh class A or B): Mean AUC increased by 64 or 84%. respectively.1 After IV administration, half-life increased to 224 or 302 hours, respectively, compared with 123 hours in healthy individuals.12

Mild, moderate, or severe renal impairment: Pharmacokinetics not altered.1

Geriatric patients: Pharmacokinetics not affected by age.1

Stability

Storage

Oral

Capsules

20–25°C (may be exposed to 15–30°C);1 store in original package and protect from moisture.1

Parenteral

Powder for IV Infusion

2–8°C.1

Dilute immediately after reconstitution;1 alternatively, may be stored at <25°C for a maximum of 1 hour prior to dilution.1

Total time from dilution to completion of IV infusion should not exceed 6 hours when stored at room temperature or 24 hours when refrigerated at 2–8°C immediately after dilution.1 Do not freeze.1

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility1 HID

Compatible

Dextrose 5% in water

Sodium chloride 0.9%

Drug CompatibilityHID
Y-Site Compatibility

Compatible

Amikacin sulfate

Amiodarone HCl

Anidulafungin

Aztreonam

Calcium chloride

Calcium gluconate

Caspofungin acetate

Ceftolozane sulfate-tazobactam sodium

Ciprofloxacin

Cisatracurium besylate

Daptomycin

Dexmedetomidine HCl

Digoxin

Diltiazem HCl

Diphenhydramine HCl

Dobutamine HCl

Dopamine HCl

Doripenem

Doxycycline hyclate

Epinephrine

Eptifibatide

Esmolol HCl

Famotidine

Fentanyl citrate

Gentamicin sulfate

Hydrocortisone sodium succinate

Hydromorphone HCl

Imipenem-cilastatin sodium

Insulin, regular

Labetalol HCl

Levofloxacin

Lidocaine HCl

Linezolid

Lorazepam

Magnesium sulfate

Mannitol

Meperidine HCl

Mesna

Metoclopramide HCl

Midazolam HCl

Milrinone lactate

Morphine sulfate

Mycophenolate mofetil HCl

Naloxone HCl

Nesiritide

Nicardipine HCl

Nitroglycerin

Norepinephrine bitartrate

Octreotide acetate

Ondansetron HCl

Phenylephrine HCl

Potassium chloride

Ranitidine HCl

Rocuronium bromide

Sodium nitroprusside

Tacrolimus

Tigecycline

Tobramycin sulfate

Vancomycin HCl

Vasopressin

Vecuronium bromide

Incompatible

Albumin human

Amphotericin B

Amphotericin B lipid complex

Amphotericin B liposomal

Ampicillin sodium-sulbactam sodium

Cefazolin sodium

Cefepime HCl

Ceftaroline fosamil

Ceftazidime

Ceftriaxone sodium

Cefuroxime sodium

Colistimethate sodium

Cyclosporine

Dexamethasone sodium phosphate

Ertapenem sodium

Esomeprazole sodium

Filgrastim

Fosphenytoin sodium

Furosemide

Heparin sodium

Meropenem

Meropenem-vaborbactam

Methylprednisolone sodium succinate

Micafungin sodium

Pantoprazole sodium

Phenytoin sodium

Potassium phosphates

Propofol

Sodium bicarbonate

Sodium phosphates

Tedizolid phosphate

Variable

Azithromycin

Bumetanide

Penicillin G potassium

Piperacillin sodium-tazobactam sodium

Actions and Spectrum

  • Triazole antifungal;1 5 6 7 8 9 structurally similar to fluconazole and voriconazole.7 22

  • Isavuconazonium is a prodrug and is inactive until hydrolyzed in the blood to isavuconazole.1 6 7 8 9

  • Like other triazole antifungals, inhibits 14-α-demethylase, which leads to accumulation of methylated sterols (e.g., 14-α-methylated lanosterol, 4,14-dimethylzymosterol, 24-methylenedihydrolanosterol) and decreased concentrations of ergosterol in fungal cell membranes.1 6 7 8 Depletion of ergosterol affects cell membrane integrity and function and can lead to fungal cell death.1 6 7

  • Aspergillus: Active in vitro and in clinical infections against A. flavus,1 8 14 19 20 21 23 24 A. fumigatus,1 8 14 19 20 21 23 24 and A. niger.1 8 14 19 20 21 23 24 Also has in vitro activity against A. lentulus,8 23 A. nidulans,8 14 20 21 23 24 A. sydowii,23 A. terreus,8 14 19 20 21 23 24 A. versicolor,8 and A. welsitschiae.23

  • Mucorales: Active in vitro and in clinical infections against fungi in the order Mucorales, including Rhizopus (R. oryzae, R. azygospurus, R. microsporus),1 8 19 Mucor (M. amphibiorum,1 M. circinelloides1 8 14 ), Lichtheimia (L. corymbifera; formerly Absidia corymbifera),1 8 14 and Rhizomucor (R. pusillus).1 8 14 19 In vitro, less active against Mucorales compared with Aspergillus.8 23

  • Candida: Active in vitro against C. albicans,8 14 19 20 23 24 28 C. dubliniensis,8 14 19 23 24 C. glabrata,8 14 18 19 20 23 24 28 C. guilliermondii,8 14 18 19 23 C. kefyr,23 28 C. krusei,8 14 18 19 20 23 24 28 C. lusitaniae,8 14 19 23 28 C. orthopsilosis,8 23 C. parapsilosis,8 14 19 20 23 24 28 and C. tropicalis.8 14 19 20 23 24 28 Some strains of C. auris (often misidentified as C. haemulonii, C. famata, or Rhodotorula glutinis) inhibited in vitro by isavuconazole concentrations of 0.004–0.25 mcg/mL.25 26 27 Has in vitro activity against some Candida with reduced susceptibility or resistance to fluconazole.6 14 19

  • Other fungi: Although clinical importance unclear, active in vitro against Blastomyces dermatitidis,14 Coccidioides posadasii,14 Cryptococcus gattii,8 14 C. neoformans,8 14 19 23 24 Geotrichum capitatum,8 14 Histoplasma capsulatum,8 14 Penicillium,19 Pichia,14 Rhodotorula,8 14 Saccharomyces cerevisiae,8 14 23 24 Scedosporium,8 14 19 Trichosporon,14 19 and dermatophytes (Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Epidermophyton floccosum, Microsporum canis).8 14

  • Resistance or reduced susceptibility to isavuconazole may occur.1 5 6 8 14 18 22 Aspergillus23 24 and Candida23 24 28 with reduced susceptibility or resistance to isavuconazole reported.

  • Cross-resistance can occur between isavuconazole and other azole antifungals (e.g., itraconazole, voriconazole).1 5 8 19 22 24

Advice to Patients

  • Isavuconazonium can be taken with or without food.1

  • Importance of swallowing capsules whole, without crushing, chewing, dissolving, or opening.1

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, and any concomitant illnesses (e.g., liver disease, familial short QT syndrome).1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • Importance of advising patients of other important precautionary information.1 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Isavuconazonium Sulfate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

186 mg (equivalent to 100 mg isavuconazole)

Cresemba

Astellas

Parenteral

For injection, for IV infusion

372 mg (equivalent to 200 mg isavuconazole)

Cresemba

Astellas

AHFS DI Essentials™. © Copyright 2019, Selected Revisions September 9, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Astellas Pharma US, Inc. Cresemba (isavuconazonium sulfate) capsules and for injection prescribing information. Northbrook, IL; 2018 Apr.

2. Food and Drug Administration. FDA Application: Search Orphan Drug Designations and Approvals. Rockville, MD. From FDA website. Accessed 2015 Apr 13. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm

3. Food and Drug Administration. Center for Drug Evaluation and Research. Application number: 207500Orig1s000/207501Orig1s000: Medical review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf

4. Food and Drug Administration. Center for Drug Evaluation and Research. Application number: 207500Orig1s000/207501Orig1s000: Clinical pharmacology and biopharmaceutics review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000ClinPharmR.pdf

5. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009; 7:981-98. http://www.ncbi.nlm.nih.gov/pubmed/19803707?dopt=AbstractPlus

6. Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013; 6:163-74. http://www.ncbi.nlm.nih.gov/pubmed/24187505?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3810441&blobtype=pdf

7. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs. 2009; 18:1279-95. http://www.ncbi.nlm.nih.gov/pubmed/19678798?dopt=AbstractPlus

8. Ananda-Rajah MR, Chang CC, and Slavin MA. Isavuconazole. In: Grayson ML, ed. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 7th ed. Boca Raton, FL: CRC Press; 2018:2858-69.

9. Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012; 8:759-65. http://www.ncbi.nlm.nih.gov/pubmed/22530880?dopt=AbstractPlus

10. Schmitt-Hoffmann A, Roos B, Heep M et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006; 50:279-85. http://www.ncbi.nlm.nih.gov/pubmed/16377698?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1346775&blobtype=pdf

11. Schmitt-Hoffmann A, Roos B, Maares J et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006; 50:286-93. http://www.ncbi.nlm.nih.gov/pubmed/16377699?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1346776&blobtype=pdf

12. Schmitt-Hoffmann A, Roos B, Spickermann J et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009; 53:4885-90. http://www.ncbi.nlm.nih.gov/pubmed/19667286?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2772314&blobtype=pdf

13. Knoll BM. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother. 2014; 69:3441-3. http://www.ncbi.nlm.nih.gov/pubmed/25114167?dopt=AbstractPlus

14. Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010; 170:291-313. http://www.ncbi.nlm.nih.gov/pubmed/20524153?dopt=AbstractPlus

15. Astellas, Northbrook, IL: Personal Communication.

16. Viljoen J, Azie N, Schmitt-Hoffmann AH et al. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother. 2015; 59:1671-9. http://www.ncbi.nlm.nih.gov/pubmed/25561337?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4325824&blobtype=pdf

17. Kullberg BJ, Viscoli C, Pappas PG et al. Isavuconazole versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. Clin Infect Dis. 2018; http://www.ncbi.nlm.nih.gov/pubmed/30289478?dopt=AbstractPlus

18. Castanheira M, Messer SA, Rhomberg PR et al. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia. 2014; 178:1-9. http://www.ncbi.nlm.nih.gov/pubmed/24952015?dopt=AbstractPlus

19. Pfaller MA, Messer SA, Rhomberg PR et al. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol. 2013; 51:2608-16. http://www.ncbi.nlm.nih.gov/pubmed/23740727?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3719620&blobtype=pdf

20. Howard SJ, Lass-Flörl C, Cuenca-Estrella M et al. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother. 2013; 57:5426-31. http://www.ncbi.nlm.nih.gov/pubmed/23959309?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3811258&blobtype=pdf

21. Arendrup MC, Howard S, Lass-Flörl C et al. EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density. Antimicrob Agents Chemother. 2014; 58:6432-6. http://www.ncbi.nlm.nih.gov/pubmed/25136005?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4249446&blobtype=pdf

22. Gregson L, Goodwin J, Johnson A et al. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. Antimicrob Agents Chemother. 2013; 57:5778-80. http://www.ncbi.nlm.nih.gov/pubmed/24041890?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3811286&blobtype=pdf

23. Pfaller MA, Rhomberg PR, Wiederhold NP et al. In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. Antimicrob Agents Chemother. 2018; 62 http://www.ncbi.nlm.nih.gov/pubmed/30061288?dopt=AbstractPlus

24. Jørgensen KM, Astvad KMT, Hare RK et al. EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mould and yeast isolates. Antimicrob Agents Chemother. 2019; http://www.ncbi.nlm.nih.gov/pubmed/30910898?dopt=AbstractPlus

25. Ruiz-Gaitán AC, Cantón E, Fernández-Rivero ME et al. Outbreak of Candida auris in Spain: A comparison of antifungal activity by three methods with published data. Int J Antimicrob Agents. 2019; 53:541-546. http://www.ncbi.nlm.nih.gov/pubmed/30769198?dopt=AbstractPlus

26. Kathuria S, Singh PK, Sharma C et al. Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. J Clin Microbiol. 2015; 53:1823-30. http://www.ncbi.nlm.nih.gov/pubmed/25809970?dopt=AbstractPlus

27. Larkin E, Hager C, Chandra J et al. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob Agents Chemother. 2017; 61 http://www.ncbi.nlm.nih.gov/pubmed/28223375?dopt=AbstractPlus

28. Desnos-Ollivier M, Bretagne S, Boullié A et al. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017). Clin Microbiol Infect. 2019; 25:634.e1-634.e4. http://www.ncbi.nlm.nih.gov/pubmed/30771532?dopt=AbstractPlus

29. Maertens JA, Raad II, Marr KA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016; 387:760-9. http://www.ncbi.nlm.nih.gov/pubmed/26684607?dopt=AbstractPlus

30. Marty FM, Ostrosky-Zeichner L, Cornely OA et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016; 16:828-837. http://www.ncbi.nlm.nih.gov/pubmed/26969258?dopt=AbstractPlus

200. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (Accessed May 21, 2019). Updates may be available at HHS AIDS Information (AIDSinfo) website. https://aidsinfo.nih.gov/guidelines

423. Patterson TF, Thompson GR, Denning DW et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63:e1-e60. Updates may be available at IDSA website at www.idsociety.org. http://www.ncbi.nlm.nih.gov/pubmed/27365388?dopt=AbstractPlus

425. Pappas PG, Kauffman CA, Andes DR et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62:e1-50. Updates may be available at IDSA website at www.idsociety.org. http://www.ncbi.nlm.nih.gov/pubmed/26679628?dopt=AbstractPlus

440. Panel on Opportunistic Infection in HIV-infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (Accessed May 13, 2019). Updates may be available at HHS AIDS Information (AIDSinfo) website https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf

HID. ASHP’s interactive handbook on injectable drugs. McEvoy, GK, ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; Updated April 13, 2018. From HID website. http://www.interactivehandbook.com/

Hide